Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220026/S014

Symplicity Spyral Renal Denervation System

Medtronic, Inc. · Decision date Sep 10, 2026

MEDTECHLEDGER EXPLANATIONP220026/S014

What did the FDA approve?

The FDA record P220026/S014 covers a labeling supplement for the Symplicity Spyral Renal Denervation System, an ablation catheter for renal denervation under product code QYI, submitted by Medtronic, Inc. The supplement type is the Normal 180 Day Track No User Fee, and its listed reason is a labeling change tied to post-approval study data.

The stated purpose is inclusion of data from post-approval studies in labeling. That statement describes a labeling action, not an independent finding of safety or clinical effectiveness. As a supplement to P220026, it modifies labeling within the existing PMA rather than approving the system anew. The record does not identify which studies, which labeling sections, or the content of any changed text.

FDA approval order statement

inclusion of data from post-approval studies in labeling
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Cardiovascular
Decision date
Sep 10, 2026
FDA change category
Labeling Change - PAS

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220026/S014
Regulatory pathway
PMA supplement
Product code
QYI
Decision code
APPR
Decision date
Sep 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Ablation catheter, renal denervation.

Product code
QYI
FDA device class
3

For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220026 · Original PMA

    Symplicity Spyral Renal Denervation System

  2. P220026/S014 received

    Application receipt date recorded by FDA.

  3. P220026/S014 · FDA decision

    Normal 180 Day Track No User Fee

  4. P220026/S019 · Related supplement

    Symplicity G3 Renal Denervation RF Generator

Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220026

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalNov 17, 2023FDA
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records